Regulation of TFEB and V-ATPases by mTORC1
What this study shows
Using Tsc2-null and wild-type mouse fibroblasts with and without rapamycin, the authors looked for genes whose expression follows mTORC1 activity and found 75 genes, enriched for subunits of the lysosomal proton pump (V-ATPase). mTORC1 also raised V-ATPase expression in mouse liver after Tsc1 deletion and in a prostate tumour model, through a transcriptional mechanism that needed the transcription factor TFEB: knocking down Tfeb cut the number of mTORC1-induced genes from 1146 to 424 probes, and about a quarter of mTORC1-induced genes depended on Tfeb. mTORC1 promoted albumin uptake (endocytosis) in a Tfeb- and V-ATPase-dependent way. In these serum-deprived cells, active mTORC1 (TSC loss) increased nuclear TFEB and rapamycin or Raptor knockdown reduced it, which is the opposite direction to the TFEB inhibition reported by later studies in fed or starved cells. Boundary: Mostly mouse and human cell lines under low serum; liver and prostate data are expression measurements. The direction of mTORC1 control over TFEB localisation here differs from later work and is condition-dependent.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Tsc2-/- vs Tsc2+/+ immortalized MEFs (serum-deprived, +/- rapamycin) with microarrays; Tsc1 floxed primary MEFs and mouse liver (Ad-Cre); myr-Akt prostate model with everolimus (public data); HeLa cells with TSC2/Raptor knockdown) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Tsc2-/- vs Tsc2+/+ immortalized MEFs (serum-deprived, +/- rapamycin) with microarrays; Tsc1 floxed primary MEFs and mouse liver (Ad-Cre); myr-Akt prostate model with everolimus (public data); HeLa cells with TSC2/Raptor knockdown |
| Journal | EMBO Journal |
| Year | 2011 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1038/emboj.2011.257 · PMID 21804531 · Free full text (PMC3160667) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Tsc2 or Tsc1 loss (genetic), rapamycin, Raptor knockdown; Tfeb knockdown |
| Target | mTORC1 -> TFEB -> V-ATPase genes |
| Model | Mouse cells and mouse liver; human HeLa cells |
| Effect | mTORC1 activation increased V-ATPase and lysosomal gene expression and endocytosis in a TFEB-dependent way; under low serum it increased TFEB nuclear localisation |
In the Atlas
Related topics
Links in the pathway map
- Supports TFEB activates Lysosomal biogenesis
- Points the other way on mTORC1 inhibits TFEB
More studies on this topic
- A TBK1/ULK1 signalling axis couples lysosomal stress to TFEB activation. (2026)
- Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes (2017)
- Dynamics of mTORC1 activation in response to amino acids (2016)
- mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase (2011)
Thank you. Your answer was counted anonymously.